Ozekibart (INBRX-109) Phase 2 Trial
Phase 2 placebo-controlled randomized study of the tetravalent DR5 agonist Ozekibart (INBRX-109) in patients with unresectable or metastatic conventional chondrosarcoma.
ClinicalTrials.gov
Key Eligibility Criteria:
+ Conventional chondrosarcoma, unresectable or metastatic
+ Available archival tissue or fresh tumor biopsy
+ Radiographic progression per RECIST 1.1 within 6 months of study treatment initiation
+ Adequate hepatic function
+ No chronic liver diseases; Exception: Patients with fatty liver disease are acceptable as long as adequate hepatic function as defined in the inclusion/exclusion criteria is confirmed
+ No clinically significant or uncontrolled comorbidities